

1P-792-T100

Monoclonal Antibody to CD87 Phycoerythrin (PE) conjugated (100 tests)

Clone: VIM5

Isotype: Mouse IgG1

Specificity: The mouse monoclonal antibody VIM5 recognizes CD87 (urokinase plasminogen

activator receptor), a 36-68 kDa single-chain GPI-anchored glycoprotein expressed on granulocytes, monocytes/macrophages, dendritic cells, endothelial cells,

fibroblasts and keratinocytes. HLDA VI; WS Code MR13

Regulatory Status: RUO

Immunogen: human myeloid cell line THP-1

Species Reactivity: Human

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography and

adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

10 µl reagent / 100 µl of whole blood or 10⁶ cells in a suspension.

The content of a vial (1 ml) is sufficient for 100 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD87, the urokinase plasminogen activator receptor (UPAR), is a GPI-anchored

single chain glycoprotein of a 50-68 kDa, which is expressed on granulocytes, monocytes/macrophages, dendritic cells, endothelial cells, fibroblasts and keratinocytes. The urokinase plasminogen activator bound to CD87 converts plasminogen to plasmin, and being concentrated on the leading edge of migrating cells, it plays important role in cell adhesion and chemotaxis. CD87 binds to β1, β2, and β3 integrins, and can contribute to cancer cell invasion and metastasis. This antigen can also be used to study normal and

abnormal granulopoiesis.

References: *Elghetany MT, Patel J, Martinez J, Schwab H: CD87 as a marker for terminal

granulocytic maturation: assessment of its expression during granulopoiesis.

Cytometry B Clin Cytom. 2003 Jan;51(1):9-13.

*Lanza F, Castoldi GL, Castagnari B, Todd RF 3rd, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti MG, Traniello S: Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic

cells. Br J Haematol. 1998 Oct;103(1):110-23.

*Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mass calls expressing the D816V-mutated

oncogenic variant of KIT. Haematologica. 2007 Nov;92(11):1451-9.

For laboratory research only, not for drug, diagnostic or other use.



PRODUCT DATA SHEET

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.